Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies

Xiaoyu Wang,Yumin Xia

DOI: https://doi.org/10.3389/fimmu.2019.01667

IF: 7.3

2019-07-17

Frontiers in Immunology

Abstract:Systemic lupus erythematosus (SLE) is characterized by high-titer serological autoantibodies, including antibodies that bind to double-stranded DNA (dsDNA). The origin, specificity, and pathogenicity of anti-dsDNA antibodies have been studied from a wider perspective. These autoantibodies have been suggested to contribute to multiple end-organ injuries, especially to lupus nephritis, in patients with SLE. Moreover, serum levels of anti-DNA antibodies fluctuate with disease activity in patients with SLE. By directly binding to self-antigens or indirectly forming immune complexes, anti-dsDNA antibodies can accumulate in the glomerular and tubular basement membrane. These autoantibodies can also trigger the complement cascade, penetrate into living cells, modulate gene expression, and even induce profibrotic phenotypes of renal cells. In addition, the expression of suppressor of cytokine signaling 1 is reduced by anti-DNA antibodies simultaneously with upregulation of profibrotic genes. Anti-dsDNA antibodies may even participate in the pathogenesis of SLE by catalyzing hydrolysis of certain DNA molecules or peptides in cells. Recently, anti-dsDNA antibodies have been explored in greater depth as a therapeutic target in the management of SLE. A substantial amount of data indicates that blockade of pathogenic anti-dsDNA antibodies can prevent or even reverse organ damage in murine models of SLE. This review focuses on the recent research advances regarding the origin, specificity, classification, and pathogenicity of anti-dsDNA antibodies and highlights the emerging therapies associated with them.

immunology

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the origin, specificity, pathogenicity of anti - double - stranded DNA (dsDNA) antibodies in systemic lupus erythematosus (SLE) and the possibility of them as therapeutic targets. Specifically, the article explores the following aspects:

1. **Origin of anti - dsDNA antibodies**:
- Normally, nuclear antigens such as dsDNA are not accessible to the immune system because they are confined within the nucleus and mitochondria, and are rapidly degraded by DNase in the cytoplasm and endosomes.
- However, when cells are exposed to ultraviolet light, infection or drugs, apoptotic cells will release nuclear materials. During NETosis, cells will release DNA and neutrophil extracellular traps (NETs), in which the DNA is covered with antibacterial substances; during apoptosis, DNA breaks to form apoptotic bodies containing DNA; during necrosis, high - molecular - weight DNA is released after cell lysis.

2. **Pathogenicity of anti - dsDNA antibodies**:
- Anti - dsDNA antibodies can directly or indirectly bind to renal antigens to form immune complexes, leading to kidney damage.
- These antibodies can cause inflammatory reactions and fibrosis through multiple mechanisms, such as activating the complement system, penetrating living cells, regulating gene expression and inducing a pro - fibrotic phenotype.
- Immune complexes are deposited in the glomerular and tubular basement membranes, triggering the complement cascade reaction and resulting in tissue damage.

3. **Detection of anti - dsDNA antibodies**:
- Several methods for detecting anti - dsDNA antibodies are introduced, including Farr radioimmunoassay (FARR - RIA), Crithidia luciliae fluorescence immunoassay (CLIFT) and enzyme - linked immunosorbent assay (ELISA), and the advantages and limitations of each method are discussed.
- It is emphasized that at least two detection methods are required to more accurately assess the presence and activity of these antibodies.

4. **Anti - dsDNA antibodies as therapeutic targets**:
- The possibility of blocking pathogenic anti - dsDNA antibodies to prevent or reverse organ damage in SLE patients is explored.
- Some emerging treatment methods are mentioned, such as synthesizing peptides that mimic the molecular structure of DNA. These peptides can specifically recognize and interact with anti - dsDNA antibodies, thereby inhibiting their antigen - recognition ability.

Through these studies, the paper aims to provide an in - depth understanding of the role of anti - dsDNA antibodies in the pathogenesis of SLE and provide a theoretical basis for the development of new treatment strategies.